scholarly journals Exam 1: Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis

2022 ◽  
Vol 20 (2) ◽  
pp. e335-e336
Keyword(s):  
Systematic Review ◽  
Trend Analysis ◽  
Esophageal Adenocarcinoma ◽  
Time Trend ◽  
Meta Analysis

scholarly journals Magnitude and Time-trend analysis of Post-Endoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Tarek Sawas ◽  
Abdul Mounaem Majzoub ◽  
James Haddad ◽  
Thomas Tielleman ◽  
Tarek Nayfeh ◽  
...  
Keyword(s):  
Systematic Review ◽  
Trend Analysis ◽  
Esophageal Adenocarcinoma ◽  
Time Trend ◽  
Meta Analysis

Fr160 MAGNITUDE AND TIME-TREND ANALYSIS OF POST-ENDOSCOPY ESOPHAGEAL ADENOCARCINOMA (PEEC): A SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

2021 ◽  
Vol 160 (6) ◽  
pp. S-242
Author(s):  
Tarek Sawas ◽  
Abdul Mounaem Majzoub ◽  
James D. Haddad ◽  
Thomas Tielleman ◽  
Tarek Nayfeh ◽  
...  
Keyword(s):  
Systematic Review ◽  
Trend Analysis ◽  
Esophageal Adenocarcinoma ◽  
Time Trend ◽  
Meta Analysis

ID: 3524312 OUTCOMES FOR ENDOSCOPIC RESECTION OF T1B ESOPHAGEAL ADENOCARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

2021 ◽  
Vol 93 (6) ◽  
pp. AB292-AB293
Author(s):  
Don C. Codipilly ◽  
Apoorva K. Chandar ◽  
Lovekirat Dhaliwal ◽  
Amitabh Chak ◽  
Kenneth K. Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Esophageal Adenocarcinoma ◽  
Endoscopic Resection ◽  
Meta Analysis

scholarly journals Surveillance in Patients With Barrettʼs Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 6 (12) ◽  
pp. e131 ◽  
Author(s):  
Yao Qiao ◽  
Ayaz Hyder ◽  
Sandy J Bae ◽  
Wasifa Zarin ◽  
Tyler J OʼNeill ◽  
...  
Keyword(s):  
Systematic Review ◽  
Early Detection ◽  
Esophageal Adenocarcinoma ◽  
Meta Analysis

Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: A systematic review and meta-analysis.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 11-11
Author(s):  
Preet Paul Singh ◽  
Siddharth Singh ◽  
Sushil Kumar Garg ◽  
Prasad G. Iyer ◽  
Hashem El-Serag
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Barrett’S Esophagus ◽  
Esophageal Adenocarcinoma ◽  
Barrett's Esophagus ◽  
Observational Studies ◽  
Meta Analysis ◽  
Number Needed To Treat ◽  
Case Control Studies ◽  
Inconsistency Index

11 Background: Acid-suppressive medications, particularly proton pump inhibitors (PPI), may modify risk of esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE). We performed a systematic review and meta-analysis of studies evaluating the association between PPIs and histamine receptor antagonists (H2RA) and risk of EAC or high-grade dysplasia (BE-HGD) in patients with BE. Methods: Through a systematic search up to June 2013, we identified 7 observational studies (5 cohort studies and 2 case-control studies; 2,813 patients with BE, 317 cases of EAC and/or BE-HGD, 84.4% PPI users) reporting the association between PPIs or H2RA and EAC in patients with BE. Summary odds ratio (OR) with 95% confidence intervals (CI) was estimated using random effects model, and heterogeneity was measured using the inconsistency index (I2). Results: On meta-analysis, PPI use was associated with 71% reduction in EAC risk in patients with BE (adjusted OR, 0.29; 95% CI, 0.12-0.71). There was a trend toward a dose-response relationship with PPI use for >2 years protective against EAC [3 studies; PPI use >2 years vs. <2 years (as compared to no use): OR, 0.45 (0.19-1.06) vs. 1.09 (0.47-2.56)]. Considerable heterogeneity was observed in the overall analysis (I2=81%). On restricting analysis to 5 cohort studies, use of PPIs was consistently associated with a lower risk of EAC and/or BE-HGD (adjusted OR, 0.33; 95% CI, 0.19-0.58; I2=9%). H2RA use was not associated with decreased risk of EAC in patients with BE based on 2 studies (adjusted OR, 1.15; 95% CI, 0.77-1.72). Using a 67% summary risk reduction (derived from cohort studies) of EAC and/or BE-HGD with PPI use in patients with BE, and observed cumulative incidence rates of EAC and/or BE-HGD in patients with BE overall as 10.2 per 1,000 patient years, we estimate the number needed to treat with PPIs to prevent 1 case of EAC or BE-HGD in BE patients at 147. Conclusions: Based on meta-analysis of observational studies, the use of PPI, but not H2RA appears to be associated with a decreased risk of EAC and/or BE-HGD in patients with BE. PPI use should be considered in BE, and chemopreventive trials of PPIs in patients with BE are warranted.

Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis

2010 ◽  
Vol 8 (3) ◽  
pp. 235-244 ◽  
Author(s):  
Marjolein Sikkema ◽  
Pieter J.F. de Jonge ◽  
Ewout W. Steyerberg ◽  
Ernst J. Kuipers
Keyword(s):  
Systematic Review ◽  
Barrett’S Esophagus ◽  
Esophageal Adenocarcinoma ◽  
Barrett's Esophagus ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document